Fulgent Genetics Stock Probability Of Bankruptcy
| FLGT Stock | USD 20.09 0.63 3.04% |
Fulgent | Probability Of Bankruptcy |
Fulgent Genetics Company probability of financial unrest Analysis
Fulgent Genetics' Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
More About Probability Of Bankruptcy | All Equity Analysis
Probability Of Bankruptcy | = | Normalized | | Z-Score |
Current Fulgent Genetics Probability Of Bankruptcy | Less than 9% |
Most of Fulgent Genetics' fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Fulgent Genetics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of Fulgent Genetics probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Fulgent Genetics odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Fulgent Genetics financial health.
Is Fulgent Genetics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fulgent Genetics. If investors know Fulgent will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fulgent Genetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.99) | Earnings Share (5.63) | Revenue Per Share 9.71 | Quarterly Revenue Growth 0.041 | Return On Assets (0.03) |
The market value of Fulgent Genetics is measured differently than its book value, which is the value of Fulgent that is recorded on the company's balance sheet. Investors also form their own opinion of Fulgent Genetics' value that differs from its market value or its book value, called intrinsic value, which is Fulgent Genetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fulgent Genetics' market value can be influenced by many factors that don't directly affect Fulgent Genetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fulgent Genetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fulgent Genetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fulgent Genetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Fulgent Probability Of Bankruptcy Driver Correlations
Understanding the fundamental principles of building solid financial models for Fulgent Genetics is extremely important. It helps to project a fair market value of Fulgent Stock properly, considering its historical fundamentals such as Probability Of Bankruptcy. Since Fulgent Genetics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Fulgent Genetics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Fulgent Genetics' interrelated accounts and indicators.
Click cells to compare fundamentals
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
| Competition |
Based on the latest financial disclosure, Fulgent Genetics has a Probability Of Bankruptcy of 9.0%. This is 79.21% lower than that of the Health Care Providers & Services sector and 77.96% lower than that of the Health Care industry. The probability of bankruptcy for all United States stocks is 77.4% higher than that of the company.
Fulgent Probability Of Bankruptcy Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Fulgent Genetics' direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Fulgent Genetics could also be used in its relative valuation, which is a method of valuing Fulgent Genetics by comparing valuation metrics of similar companies.Fulgent Genetics is currently under evaluation in probability of bankruptcy category among related companies.
Fulgent Genetics Main Bankruptcy Drivers
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Return On Assets | 0.004124 | 0.31 | 0.4 | 0.1 | (0.13) | (0.14) | |
| Gross Profit Margin | 0.57 | 0.79 | 0.78 | 0.59 | 0.33 | 0.44 | |
| Net Debt | (9.3M) | (71.6M) | (143.6M) | (58.9M) | (82.6M) | (78.4M) | |
| Total Current Liabilities | 6.0M | 131.1M | 112.8M | 116.2M | 73.0M | 49.4M | |
| Non Current Liabilities Total | 2.3M | 959K | 7.5M | 28.1M | 66.8M | 70.1M | |
| Total Assets | 88.8M | 700.5M | 1.3B | 1.4B | 1.3B | 1.3B | |
| Total Current Assets | 76.8M | 615.7M | 1.1B | 905.6M | 507.8M | 365.6M | |
| Total Cash From Operating Activities | 5.5M | 140.6M | 538.6M | 253.5M | 27.0M | 25.7M |
Fulgent Fundamentals
| Return On Equity | -0.15 | ||||
| Return On Asset | -0.0347 | ||||
| Profit Margin | (0.58) % | ||||
| Operating Margin | (0.47) % | ||||
| Current Valuation | 203.76 M | ||||
| Shares Outstanding | 29.9 M | ||||
| Shares Owned By Insiders | 32.58 % | ||||
| Shares Owned By Institutions | 49.20 % | ||||
| Number Of Shares Shorted | 603.98 K | ||||
| Price To Earning | 3.95 X | ||||
| Price To Book | 0.55 X | ||||
| Price To Sales | 2.15 X | ||||
| Revenue | 289.21 M | ||||
| Gross Profit | 366.9 M | ||||
| EBITDA | (43.54 M) | ||||
| Net Income | (167.82 M) | ||||
| Cash And Equivalents | 515.4 M | ||||
| Cash Per Share | 17.03 X | ||||
| Total Debt | 14.91 M | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 5.29 X | ||||
| Book Value Per Share | 38.31 X | ||||
| Cash Flow From Operations | 27 M | ||||
| Short Ratio | 2.23 X | ||||
| Earnings Per Share | (5.63) X | ||||
| Price To Earnings To Growth | 1.32 X | ||||
| Target Price | 26.67 | ||||
| Number Of Employees | 1.18 K | ||||
| Beta | 1.42 | ||||
| Market Capitalization | 619.54 M | ||||
| Total Asset | 1.27 B | ||||
| Retained Earnings | 633.17 M | ||||
| Working Capital | 434.83 M | ||||
| Current Asset | 2.93 M | ||||
| Current Liabilities | 686 K | ||||
| Net Asset | 1.27 B |
About Fulgent Genetics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Fulgent Genetics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Fulgent Genetics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Fulgent Genetics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Fulgent Genetics Piotroski F Score and Fulgent Genetics Altman Z Score analysis. For more information on how to buy Fulgent Stock please use our How to Invest in Fulgent Genetics guide.Note that the Fulgent Genetics information on this page should be used as a complementary analysis to other Fulgent Genetics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Complementary Tools for Fulgent Stock analysis
When running Fulgent Genetics' price analysis, check to measure Fulgent Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulgent Genetics is operating at the current time. Most of Fulgent Genetics' value examination focuses on studying past and present price action to predict the probability of Fulgent Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulgent Genetics' price. Additionally, you may evaluate how the addition of Fulgent Genetics to your portfolios can decrease your overall portfolio volatility.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |
Is Fulgent Genetics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fulgent Genetics. If investors know Fulgent will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fulgent Genetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.99) | Earnings Share (5.63) | Revenue Per Share 9.71 | Quarterly Revenue Growth 0.041 | Return On Assets (0.03) |
The market value of Fulgent Genetics is measured differently than its book value, which is the value of Fulgent that is recorded on the company's balance sheet. Investors also form their own opinion of Fulgent Genetics' value that differs from its market value or its book value, called intrinsic value, which is Fulgent Genetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fulgent Genetics' market value can be influenced by many factors that don't directly affect Fulgent Genetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fulgent Genetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fulgent Genetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fulgent Genetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.